Status and phase
Conditions
Treatments
About
This is a multi-center phase 1 open-label study to determine the safety of ABL001 and INO in patients with relapsed or refractory Philadelphia chromosome-positive b-cell acute lymphoblastic leukemia.
Full description
This study will test a combination of two drugs for people with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph-positive B-ALL), a fast-growing blood cancer. Asciminib is a targeted oral drug that is FDA-approved for chronic myeloid leukemia, but is not FDA-approved for Ph-positive B-ALL. Inotuzumab ozogamicin (also called Besponsa) is an FDA-approved treatment that uses an antibody (a protein) to deliver a small amount of chemotherapy directly to leukemia cells. It is commonly used when leukemia has come back after earlier treatment (relapsed) or has not improved with treatment (refractory). This study aims to find the safest dose of asciminib when it is given together with inotuzumab ozogamicin. The goal is to see whether this combination can provide a more effective and better tolerated treatment option for people whose leukemia has returned or has not responded to previous therapies.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Documented and confirmed CD22+ R/R Ph+ B-ALL according to the World Health Organization (WHO) classification
Disease must be positive for Ph (p190 or p210 transcript) by cytogenetics or PCR
Disease must be positive for CD22, defined as any percentage of leukemic blasts expressing CD22
Disease must be positive for t(9;22) by Cytogenetics and FISH. Subjects with complex translocations resulting in BCR::ABL1 fusion protein are eligible.
BCR-ABL mutational panel performed within 90 days prior to start of treatment, including the following 4 mutations: T315I and M244V, A337V, or F359C/I/V mutations. Specific panel may be determined per institution, however must include all aforementioned mutations. Note: T315I mutated patients are only eligible once Dose Level 3 is open to enrollment
Subject must have recovered (no worse than Grade 1 severity) from effects of all previous treatments.
Able to provide informed consent
Age ≥18 years of age
Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2 or Karnofsky ≥60%
Adequate organ function defined by the following parameters:
Female patients of childbearing potential must not be nursing or planning to become pregnant
Female patients of childbearing potential require a negative urine or serum pregnancy test within 30 days of study therapy.
Female patients of childbearing potential must be willing to use at least 1 method of highly effective contraception during the study until 8 months after last dose of inotuzumab ozogamicin, or 1 week after the last dose of asciminib, whichever is later.
Male patients who are sexually active must be willing to use condoms and refrain from sperm donation during the study until 5 months after last dose of inotuzumab ozogamicin
Willing to provide pretreatment bone marrow aspirate and biopsies samples as well as subsequent bone marrow aspirate and biopsies samples during the study.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
45 participants in 1 patient group
Loading...
Central trial contact
Research Nurse Navigator
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal